Banner
صفحه اصلی>مقالات علمی


۱۳۹۶/۰۵/۰۲       (تعداد بازدید : ۱۹۰۷)نویسنده :

EUROPEAN JOURNAL OF NEUROLOGY Volume ۲۴, Supplement ۱, June ۲۰۱۷ Abstracts of the ۳rd Congress of the European Academy of Neurology Amsterdam, The Netherlands Observational cohort study on safety and efficacy of copamer (a new brand-generic Glatiramer acetate) ۴۰mg in Iranian patients with RRMS R. Abolfazli۱, S. Pournourmohammadi۲, S. Samadzadeh۱,A.R. Shamshiri۳, J. Alaghehmandi۲ ۱Amiralam hospital, ۲Zahravi Pharmaceutical Company, Tehran, Iran, Islamic Republic of, ۳School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Objective: The aim of this study is to evaluate the safety, tolerability and efficacy of a brand-generic Glatiramer acetate (GA) ۴۰ mg, in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) over a ۱۲-month period.
بیشتر بخوانید
۱۳۹۵/۰۳/۱۲       (تعداد بازدید : ۳۷۵۰)نویسنده : Shirin Pournourmohammadi, Zhaleh Alaghebandi

Introduction: Glatiramer acetate is a synthetic amino acid polymer used for relapsing remitting multiple sclerosis. Glatiramer acetate ۲۰, ۴۰ mg/ml prefilled syringe produced by Zahravipharmaceutical Company (Copamer ®) are in the market for a few years. According to standard guidelines, assessment of safety of products after marketing authorization shall be accomplished by manufacturer. The objective of this study was to investigate occurrence and frequency of adverse drug reactions associated to Copamer used by patients with multiple sclerosis.
بیشتر بخوانید
۱۳۹۵/۰۲/۱۴       (تعداد بازدید : ۴۰۳۸)نویسنده : Zahra Rezaieyazdi, Tahmine Tavakoli, Mohammad Khajehdaluee and Shahram Honarmand

Abstract Background: Mycophenolate mofetil (MMF) has long been used to manage lupus nephritis. Despite research on its long-term efficacy, it is still warranted to conduct further investigation regarding its indications, safety and outcome. This study was intended to evaluate our proposed protocol in maintenance therapy with MMF. Twenty-four lupus nephritis patients were registered prior to their receiving ۳–۶ month induction therapy with monthly iv pulses of cyclophosphamide (CYC), followed by ۲۴ month maintenance therapy using MMF and steroid. We defined end points as achievement of complete and partial remission, relapse, refractory to therapy as well as end stage renal disease (ESRD) and death. Friedman and repeated measurement tests were used to assess the effect of treatment on parameters over time.
بیشتر بخوانید
۱۳۹۴/۱۰/۱۹       (تعداد بازدید : ۲۸۳۰)نویسنده :

in the plasma lipid and lipoprotein metabolism, and increased oxidative stress. This study aimed to investigate the effects of active vitamin D on serum lipids and oxidative stress markers in type ۲ diabetic patients.
بیشتر بخوانید